ARTICLE | Clinical News
Aliskiren: Phase IIb
October 15, 2001 7:00 AM UTC
Results of Phase IIb trial in Ireland in 226 patients comparing Aliskiren to Losartan, an angiotensin II receptor inhibitor marketed by Merck and Co. Inc. (MRK, Whitehouse Station, N.J.), showed that ...